ARS Pharmaceuticals (SPRY) Profit After Tax (QoQ) (2020 - 2026)
ARS Pharmaceuticals (SPRY) Profit After Tax (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 471.57 Bn | 466.77 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.01 Bn | 114.76 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn |
| 10 | ARS Pharmaceuticals | 558.54 Mn | 357.57 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -46.35% |
| Dec 31, 2025 | 18.96% |
| Sep 30, 2025 | -13.58% |
| Jun 30, 2025 | -32.59% |
| Mar 31, 2025 | -167.74% |
| Dec 31, 2024 | 368.75% |
| Sep 30, 2024 | -48.71% |
| Jun 30, 2024 | -19.80% |
| Mar 31, 2024 | -46.00% |
| Dec 31, 2023 | 51.78% |
| Sep 30, 2023 | 15.62% |
| Jun 30, 2023 | -15.15% |
| Mar 31, 2023 | -6.04% |
| Dec 31, 2022 | -119.19% |
| Sep 30, 2022 | -2.54% |
| Jun 30, 2022 | 11.45% |
| Mar 31, 2022 | -115.83% |
| Dec 31, 2021 | 301.90% |
| Sep 30, 2021 | 7.38% |
| Jun 30, 2021 | -29.84% |